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Dialysis modalities and dyslipidemia. Progressive renal failure contributing factors to a decreased catabolism include
is accompanied by dyslipidemia, which is reflected in an abnor- a reduced activity of lipolytic enzymes, compositional
mal apolipoprotein profile. It is characterized by increased abnormalities of lipoproteins as substrates for lipolysis,concentrations of intact and partially metabolized triglyceride-
and a decreased receptor-mediated uptake of lipopro-rich apoB-containing lipoproteins. They occur preferentially
teins [1]. The pathophysiologic links to loss of renal func-in very-low density lipoprotein (VLDL) and low-density lipo-
protein (LDL) as a result of impaired metabolism and clear- tion are still not clearly defined, but changes in insulin-
ance. Hemodialysis can moderately attenuate the renal dyslipi- mediated processes and insulin resistance appear to be
demia. In contrast, peritoneal dialysis is associated with further
of significance [1].aggravation, including an increase of cholesterol-rich apoB-
Treatment with dialysis is effective for ameliorationcontaining lipoproteins.
of uremic symptoms and certain features of uremic toxic-
ity. An important question is to what extent can dialysis
and the choice of dialysis modality influence the expres-
sion of dyslipidemia in patients with renal failure? Renal
RENAL DYSLIPIDEMIA dyslipidemia was first described in hemodialysis (HD)
Progressive renal failure is associated with characteris- populations, with elevated plasma triglyceride levels as
tic alterations of lipoprotein metabolism and dyslipide- the main characteristic finding. There are several possi-
mia [1]. In many patients, the dyslipidemia may not be ble ways in which dialysis treatment may modify renal
expressed as hyperlipidemia (i.e., elevated plasma levels dyslipidemia, including attenuation of uremic toxicity
of cholesterol and/or triglycerides). The renal dyslipide- as well as specific effects of the dialysis modality. The
mia is reflected in an abnormal apolipoprotein (apo) consequences of long-term dialysis on nutrition and the
profile and in the concentrations and composition of accompanying pharmacologic treatment may be addi-
individual lipoprotein families [1, 2]. It is characterized tional contributing factors.
by reduced concentrations of apoA-containing lipopro-
teins in high-density lipoprotein (HDL) and increased
HEMODIALYSIS AND DYSLIPIDEMIAconcentrations of intact or partially metabolized triglyc-
eride-rich apoB-containing lipoproteins in VLDL, inter- Studies have indicated that the characteristic features
mediate-density lipoprotein (IDL), and LDL [1, 3]. of renal dyslipidemia remain essentially unchanged dur-
There is a preferential increase in the levels of IDL ing long-term HD [1, 7]. Depending on the criteria, up
and small dense LDL [3, 4], but little change in the to 70% of HD patients have hyperlipidemia, mainly a
concentrations of cholesterol-rich apoB-containing lipo- moderate elevation of plasma triglycerides. The apolipo-
proteins. A significantly decreased plasma apoA-I to protein profile retains the main characteristics of the
apoC-III ratio is the hallmark of the altered lipoprotein dyslipidemia observed in patients with less advanced re-
composition in renal disease. It is detected at the early nal failure, including reduced apoA-I and apoA-II levels,
asymptomatic stages of renal insufficiency and will be- moderate elevations of apoB and apoE, and a significant
come further accentuated as renal failure develops [5, 6]. increase of apoC-III concentrations [7]. Even in patients
The principal disturbance of the lipoprotein metabo- without hyperlipidemia, there is an increase in apoC-III
lism appears to be a reduced catabolism and clearance of and VLDL-cholesterol and a decrease in HDL-choles-
triglyceride-rich apoB-containing lipoproteins; the main terol levels [7, 8]. The increase of apoC-III occurs prefer-
entially among the apoB-containing lipoproteins [7]. By
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levels of lipoprotein B (LpB), the characteristic choles- of triglyceride-rich apoB-containing lipoproteins, there
terol-rich lipoprotein of LDL [7]. In contrast, there is is also an elevation of cholesterol-rich apoB-containing
an increase in the levels of triglyceride-rich apoB-con- lipoproteins, as reflected by increased levels of both IDL
taining lipoproteins, which, in addition to apoB, also and LDL [7, 9, 16]. The characteristic reduction of apoA-
contain apoC and/or apoE, resulting in a marked in- containing lipoproteins in HDL of patients with less ad-
crease of apoB-containing lipoproteins in IDL [9]. The vanced renal failure and HD patients is also shared by
distribution of apoC-III in lipoprotein fractions is similar PD patients [7, 9, 15, 16].
to that occurring in patients before dialysis [3, 6]. Com- We have shown in a recent study that PD patients
pared with patients before dialysis, HD patients have have significantly higher levels of both cholesterol-rich
slightly lower concentrations of the triglyceride-rich lipo- and triglyceride-rich apoB-containing lipoproteins than
proteins, possibly representing an attenuation of the dys- HD patients [7]. In view of the documented atherogenic
lipidemia [7]. potential of both triglyceride-rich and cholesterol-rich
Recent studies have shown that VLDL and IDL from apoB-containing lipoproteins, it appears that the already
HD patients do not differ from VLDL and IDL from unfavorable lipoprotein profile in HD patients is further
predialysis patients in respect to reactivity to lipoprotein aggravated in PD patients.
lipase [10]. The increased content of apoC-III in apoB- There are several features of the PD treatment that
containing lipoproteins appears to be an important factor may directly affect lipoprotein metabolism. The signifi-
associated with decreased reactivity to lipoprotein lipase cant absorption of glucose from the dialysis fluid provides
[1, 6]. a substrate for increased lipoprotein synthesis that may
The HD procedure includes factors that may influence result in elevated plasma lipid concentrations [16]. In
the lipoprotein metabolism. The use of low-molecular
support of this, modification of the PD procedure withweight heparins for anticoagulation have, in some, but
the use of icodextrin-containing dialysis solutions insteadnot all studies, led to a moderate reduction of triglyceride
of glucose for the overnight dwell results in a moderatelevels in comparison with the use of unfractionated hepa-
reduction of plasma cholesterol [19]. The failure to dem-rin. This may be related to the effect of low-molecular
onstrate a direct correlation between glucose absorptionweight heparins on release and clearance of lipoprotein
and lipid levels may be due to the fact that almost alllipase. Studies on the influence of high-flux dialysis mo-
patients have a significant absorption of glucose in adalities, such as hemodiafiltration or hemofiltration, have
range that does not permit correlation analysis [16]. Theyielded conflicting results [11, 12, 13]. However, we have
peritoneal protein clearance may, in addition to albumin,recently shown that the choice of dialysis membrane
include apolipoproteins and HDL, and possibly otherdoes not influence the dyslipidemia [13].
lipoprotein regulatory substances, which may triggerIt is of interest to note that treatment of hyperphos-
mechanisms that resemble those operative in nephroticphatemia with the resin sevelamer hydrochloride (HCl)
syndrome, particularly an increase of cholesterol-richhas resulted in a significant decrease in the levels of
plasma cholesterol and apoB in hemodialysis patients lipoproteins [7, 9, 20].
[14]. Sevelamer HCl is known to bind bile acids, as well In summary, in PD patients, the renal dyslipidemia
as phosphate, and therefore has a cholestyramine-like also retains its characteristic profile. However, in contrast
effect in addition to controlling serum phosphate. It is to HD, the increase of atherogenic lipoproteins is more
likely that the use of sevelamer would result in a similar pronounced.
cholesterol-lowering effect in both predialysis and peri-
toneal dialysis (PD) patients.
CONCLUSIONIn summary, the principal features of renal dyslipide-
mia remain essentially unchanged during HD, but the The dialysis modality may, to a certain extent, influ-
expression of dyslipidemia can be moderately attenuated ence the expression of renal dyslipidemia in patients with
during long-term HD. end-stage renal disease. There is a moderate attenuation
of the dyslipidemia in HD patients in contrast to its
aggravation observed in PD patients. The clinical sig-PERITONEAL DIALYSIS AND DYSLIPIDEMIA
nificance of renal dyslipidemia is not yet established butIn contrast to studies in HD patients, there are fewer
is awaiting conclusive interventional studies. However,studies of dyslipidemia in PD patients. Hyperlipidemia
results from studies in nonrenal patients strongly suggestis more prevalent in PD patients than in HD patients
that the accumulation of atherogenic lipoproteins could[7, 9, 15–18]. In addition to hypertriglyceridemia there
also play a role in the rapid development of atheroscle-is also an increase of plasma cholesterol and LDL-choles-
rotic complications in dialysis patients.terol levels [7, 9, 15–18]. The apolipoprotein profile of
PD patients is characterized by a proportionately greater
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